Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 0.0 | 4.0 |
Min SIP Amount | ₹100 | ₹500 |
Expense Ratio | 2.14 | 1.95 |
NAV | ₹16.96 | ₹436.16 |
Fund Started | 14 Sep 2023 | 04 Jun 1999 |
Fund Size | ₹1459.59 Cr | ₹3459.68 Cr |
Exit Load | Exit load of 1%, if redeemed within 30 days. | Exit load of 0.50% if redeemed within 15 days |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 49.44% | 41.77% |
3 Year | - | 22.99% |
5 Year | - | 29.69% |
1 Year
3 Year
5 Year
Equity | 98.21% | 96.50% |
Cash | 1.79% | 3.50% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 13.48% |
Divi's Laboratories Ltd. | 7.85% |
Cipla Ltd. | 7.75% |
Lupin Ltd. | 5.80% |
Gland Pharma Ltd. | 3.99% |
Ipca Laboratories Ltd. | 3.75% |
Aster DM Healthcare Ltd. | 3.57% |
Vijaya Diagnostic Centre Ltd. | 3.54% |
Eris Lifesciences Ltd. | 3.38% |
Glenmark Pharmaceuticals Ltd. | 3.37% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.87% |
Divi's Laboratories Ltd. | 6.42% |
Cipla Ltd. | 5.68% |
Max Healthcare Institute Ltd. | 5.66% |
Lupin Ltd. | 4.74% |
Lonza Group Ag | 4.39% |
Poly Medicure Ltd. | 4.02% |
Krishna Institute of Medical Sciences Ltd | 3.75% |
Jupiter Life Line Hospitals Ltd. | 3.64% |
Aether Industries Ltd. | 3.33% |
Name | Dhruv Muchhal | Tanmaya Desai |
Start Date | 14 Sep 2023 | 27 Jun 2011 |
Name
Start Date
Description | The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 14 Sep 2023 | 04 Jun 1999 |
Description
Launch Date